Research Advance of Immune Checkpoint Molecule TIGIT in Hematological Malignancies--Review.
10.19746/j.cnki.issn.1009-2137.2021.03.054
- Author:
Hui LU
1
;
Hua-Fang WANG
2
Author Information
1. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430020, Hubei Province, China.
2. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430020, Hubei Province, China,E-mail: whf2019@hust.edu.cn.
- Publication Type:Review
- MeSH:
Hematologic Neoplasms;
Humans;
Immune Checkpoint Proteins;
Immunotherapy;
Killer Cells, Natural;
Receptors, Immunologic
- From:
Journal of Experimental Hematology
2021;29(3):993-997
- CountryChina
- Language:Chinese
-
Abstract:
TIGIT is an inhibitory receptor containing T cell immunoglobulin and immune receptor protein tyrosine inhibitory motif domain. It shows high expression level on the surface of immune cells in tumor patients and plays an inhibitory role by binding to corresponding ligands, CD155 and CD112. Studying the mechanism of inhibitory effect of TIGIT and the way to block it shows a great significance in the immunotherapy of tumor. In this review, the structure of TIGIT molecule and its inhibitory effect on immune cells(including NK cells and T cells) were introduced, the expression level and the newest research advance of TIGIT molecule in lymphoma,multiple myeloma,leukemia and myelodysplastic syndrome were reviewed and summarized briefly, so as to provide reference for the further study of TIGIT and the application of TIGIT inhibitors in hematological malignancies.
